Wyeth Alesse

Wyeth-Ayerst files supplemental NDA for a moderate acne vulgaris indication for the oral contraceptive Alesse. The AHP division filed an NDA Nov. 6 for approval of .1 mg levonorgestrel/20 mcg ethinyl estradiol to treat acne in menstruating women who desire contraception and are unresponsive to topical acne medications. Ortho's Tri-Cyclen (norgestimate/ethinyl estradiol) received an acne indication in 1997